Philip la Fleur
Assistant Professor of Practice, NUSOM
Director of Center for Clinical Trials

Philip is a pharmacist/epidemiologist and a clinical trials specialist from Canada.  He has over 20 years of experience in clinical practice, clinical research, the pharmaceutical industry and health technology assessment.  Philip has worked for the pharmaceutical companies Abbott, Amgen, and GlycoDesign.  He has had responsibilities for developing, implementing and monitoring clinical research studies.  He also contributed to medical marketing and medical informatics. 
He holds a degree in pharmacy from the University of Toronto (Canada) and a Master of Science in Epidemiology from the London School of Hygiene and Tropical Medicine, University of London (UK).
As Director of the CCT, Philip is responsible for client relations and for directing the company’s strategic development including new business, contracts, investigator recruitment, site selection, biostatistical analysis and study design consultancy.

Prof. Bakytgul Yermekbayeva, MD, PhD, DMSc
Lead for Clinical Site Development, Center for Clinical Trials

Dr. Yermekbayeva is a medical doctor and graduate of Karaganda State Medical Institute (KGMI). She has over 20 years of clinical medical experience.  She worked in the ZdravPlusproject (USAID) as a Director of the Drug Information Center. From 2006 to 2011 she worked as Chief Researcher in the Laboratory of Toxicology and Pharmacology in the National Center for Biotechnology.
From 2011 to 2017, she worked as Senior Researcher in the Department of Translational Medicine, Healthy Aging and Global Health in the Center for Life Sciences.  She joined the CCT in July 2017.
Dr. Yermekbayeva has extensive training from the Vienna School of Clinical Trials (Austria), including Certification for Trainers of GCP and courses in Pharmacoeconomics.
As Lead, Clinical Site Development for the CCT, Dr. Yermekbayeva is responsible for protocol development and implementation, logistics and GCP training of investigators, contracts, regulatory and national ethics submissions and site monitoring.